Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5(b) - Pfizer Inc

20 Nov 2015 11:53

RNS Number : 4645G
J.P. Morgan Securities LLC
20 November 2015
Β 

Ap27

Β 

FORMΒ 38.5(b)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ CONNECTEDΒ EXEMPTΒ PRINCIPALΒ TRADERSΒ WITHOUTΒ RECOGNISEDΒ INTERMEDIARYΒ STATUS,Β ORΒ WITHΒ RECOGNISEDINTERMEDIARYΒ STATUSΒ BUTΒ NOTΒ DEALINGΒ INΒ AΒ CLIENT-SERVINGΒ CAPACITY

Β 

Β 

1. KEYΒ INFORMATION

Β 

Name of exempt principal trader

J.P. Morgan Securities LLC.

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common Stock

Date of dealing

19 November 2015

Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 2)

Β 

Class of relevant security:

Long

Short

Common Stock

Number

(%)

Number

(%)

(1) Relevant securities

5,291,365 0.09

3,358,115 0.05

(2) Derivatives (other than options)

1,238,608 0.02

2,496,087 0.04

(3) Options and agreements to purchase/sell

Β 8,025,670 0.13

5,279,500 0.09

Total

14,555,643 0.24

11,133,702 0.18

Β 

Β 

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 2)

Β 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Β 

Ap28

Β 

Β 

3. DEALINGSΒ (NoteΒ 3)

Β 

(a) PurchasesΒ andΒ sales

Β 

Purchases/ sales

Β 

Number of relevant securities

Price per unit (USD)

Purchases

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Sales

25,000

375,060

300

500

29,699

7,526

100

4,229

100

4,283

407

800

34,630

18,048

7,349

5,265

1,600

85

15,252

300

14,411

1,700

12,500

3,100

6

8,236

3,126

5,308

1,221

34,640

800

800

100

14

68

755

100

Β 

187,560

23,115

10

14

100

32.1000

32.1500

32.1700

32.1775

32.1797

32.1799

32.1800

32.1807

32.2500

32.2627

32.2635

32.2700

32.2900

32.2933

32.3137

32.3174

32.3200

32.3300

32.3310

32.3367

32.3481

32.3500

32.3550

32.3600

32.3700

32.3763

32.3834

32.3841

32.3934

32.3970

32.4000

32.4300

32.6500

32.7550

32.7950

32.8100

32.9300

Β 

32.1500

32.2900

32.9000

32.9300

32.9550

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit (USD)

(Note 4)

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

Call Option

Call Option

Call Option

Call Option

Call Option

Call Option

Put Option

Put Option

Put Option

Purchasing

Purchasing

Purchasing

Selling

Selling

Selling

Purchasing

Selling

Selling

200,000

1,000,000

500,000

375,000

500,000

1,000,000

1,000,000

258,200

1,000,000

34.00

32.00

32.00

33.00

32.00

32.00

32.00

32.00

32.00

American

American

American

American

American

American

American

American

American

04/12/15

20/11/15

18/03/16

20/11/15

20/11/15

18/03/16

20/11/15

20/11/15

20/11/15

0.27

0.39

2.16

0.06

0.41

2.19

0.23

0.22

0.25

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 3)

Β 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

Β 

Ap29

Β 

4. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ person disclosingΒ andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesunderΒ anyΒ optionΒ referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionorΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivative referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.IfΒ none,Β thisΒ shouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 38.5(b)Β attached?Β (NoteΒ 8) Β YES

Β 

Β 

Date of disclosure

20 November 2015

Contact name

Tung Le

Telephone number

020 7742 7272

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Adviser to Allergan plc

Β 

Β 

Β 

SUPPLEMENTALΒ FORMΒ 38.5(b)

Β 

Β 

Β 

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DETAILSΒ OFΒ OPENΒ POSITIONS

Β 

(ThisΒ formΒ shouldΒ beΒ attachedΒ toΒ FormΒ 38.5(b))Β OPENΒ POSITIONSΒ (NoteΒ 1)

Β 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)(USD)

Type, e.g. American, European etc.

Expiry date

Call option

Β 

Purchased

30,000

35.00

American

20/01/17

Call option

Purchased

70,000

37.00

American

20/01/17

Call option

Purchased

363,900

35.00

American

15/01/16

Call option

Purchased

700

38.00

American

15/01/16

Call option

Purchased

1,200,000

34.00

American

20/11/15

Call option

Written

Β 

2,500

28.00

American

15/01/16

Call option

Written

14,700

30.00

American

15/01/16

Call option

Written

200

37.00

American

15/01/16

Call option

Written

150,000

37.00

American

15/01/16

Call option

Written

50,000

33.00

American

18/12/15

Call option

Written

6,000

34.00

American

18/12/15

Call option

Written

7,600

32.00

American

15/01/16

Call option

Purchased

383,200

34.71

European

21/12/15

Call option

Purchased

383,200

34.71

European

21/12/15

Call option

Purchased

127,794

35.28

European

03/12/15

Call option

Purchased

120,533

35.66

European

12/01/16

Call option

Purchased

48,943

36.47

European

25/01/16

Call option

Written

200,000

33.00

European

16/12/16

Call option

Written

383,200

34.71

European

21/12/15

Put option

Purchased

Β 

Β 

30,000

35.00

American

20/01/17

Put option

Purchased

20,000

35.00

American

20/01/17

Put option

Purchased

4,300

30.00

American

15/01/16

Put option

Purchased

2,800

28.00

American

15/01/16

Put option

Purchased

300

32.00

American

15/01/16

Put option

Purchased

150,000

30.00

American

16/09/16

Put option

Purchased

100,000

36.00

American

18/03/16

Put option

Purchased

32,900

32.00

American

15/01/16

Put Option

Purchased

1,000,000

33.50

American

20/11/15

Put option

Written

9,200

33.00

American

19/02/16

Put option

Written

19,100

31.00

American

19/02/16

Put option

Written

5,300

23.00

American

15/01/16

Put option

Written

100,000

30.00

American

15/01/16

Put option

Written

5,600

25.00

American

15/01/16

Put option

Written

250,000

28.00

American

15/01/16

Put Option

Written

500,000

33.00

American

18/03/16

Put Option

Purchased

200,000

33.00

European

16/12/16

Put Option

Written

Β 

117,900

35.00

American

17/06/16

Put Option

Written

62,400

35.00

American

17/06/16

Put Option

Written

71,300

35.00

American

17/06/16

Put Option

Written

646,800

35.00

American

17/06/16

Put Option

Written

154,500

35.00

American

17/06/16

Put Option

Written

308,100

35.00

American

17/06/16

Put Option

Written

Β 

139,000

35.00

American

17/06/16

Put Option

Written

Β 

450,000

35.00

American

15/01/16

Callable Barrier Reverse Convertible Note

Purchased

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Purchased

30,572

32.71

N/A

21/03/17

Auto-callable Barrier Reverse Convertible Note

Purchased

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

30,408

34.53

N/A

05/04/16

Equity Linked Note

Purchased

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Purchased

14,874 +

29.12

N/A

12/09/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Written

14,874 +

29.12

N/A

12/09/16

Leveraged Accumulator

Written

9,000+

31.70

N/A

04/03/16

Auto-callable Optimization Securities

Written

7,851

27.60

N/A

25/06/20

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Leveraged Accumulator

Written

14,874 +

29.12

N/A

12/09/16

Put Option

Purchased

457,000

27.50

N/A

11/01/16

Callable Barrier Reverse Convertible

Purchased

22,929

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

7,685

32.53

N/A

15/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

11,189

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

178

2.44

N/A

05/04/16

Equity Link Note

Purchased

31,133

32.12

N/A

15/12/15

Equity Link Note

Written

31,133

32.12

N/A

15/12/15

Equity Link Note

Written

31,133

32.12

N/A

15/12/15

Put Option

Purchased

50,000

33.00

American

18/12/15

Call Option

Purchased

200,000

34.00

American

04/12/15

Call Option

Written

375,000

33.00

American

20/11/15

Put Option

Written

258,200

32.00

American

20/11/15

Call Option

Purchased

500,000

32.00

American

18/03/16

Call Option

Written

1,000,000

32.00

American

18/03/16

Call Option

Written

500,000

32.00

American

20/11/15

Call Option

Purchased

1,000,000

32.00

American

20/11/15

Put Option

Written

500,000

32.00

American

20/11/15

Put Option

Purchased

1,000,000

32.00

American

20/11/15

+ This instrument is physically settled, and the interest in shares has been calculated as the maximum number of Mylan shares that the counterparty could be obliged to buy at the exercise price

Β 

Notes

Β 

1. WhereΒ thereΒ areΒ openΒ optionΒ positionsΒ orΒ openΒ derivativeΒ positionsΒ (exceptΒ forΒ CFDs),Β fullΒ detailsΒ shouldΒ beΒ given.FullΒ detailsΒ ofΒ any existingΒ agreementsΒ toΒ purchaseΒ orΒ toΒ sellΒ mustΒ alsoΒ beΒ givenΒ onΒ this form.

Β 

2. ForΒ allΒ pricesΒ andΒ otherΒ monetaryΒ amounts,Β theΒ currencyΒ mustΒ be stated.

Β 

ForΒ fullΒ detailsΒ ofΒ disclosureΒ requirements,Β seeΒ RulesΒ 8Β and

38.5Β ofΒ theΒ Rules.Β IfΒ inΒ doubt,Β consultΒ theΒ Panel.

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEPKKDPDBDDKDB
Date   Source Headline
27th May 20143:12 pmRNSForm 8.3 - Pfizer Inc
27th May 20143:07 pmBUSForm 8.3 - Pfizer Inc
27th May 20142:30 pmRNSForm 8.3 - [AstraZeneca Plc]
27th May 20142:26 pmRNSForm 8.3 - [Pfizer Inc]
27th May 20142:03 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
27th May 20141:32 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
27th May 201412:10 pmRNSForm 8.3 - Pfizer Inc
27th May 201411:56 amRNSForm 8.5 (EPT/NON-RI)
27th May 201411:55 amRNSForm 8.3 - Pfizer Inc.
27th May 201411:54 amRNSForm 8.5 (EPT/RI) Pfizer Inc
27th May 201411:53 amRNSForm 8.5 (EPT/RI) Pfizer Inc
27th May 201411:51 amRNSForm 8.5 (EPT/RI) Pfizer Inc
27th May 201411:50 amRNSForm 8.5 (EPT/RI) Pfizer Inc
27th May 201411:50 amRNSForm 8.5 (EPT/RI) Pfizer Inc
27th May 201411:43 amRNSForm 8.5 (EPT/RI)-Pfizer Inc.
27th May 201411:39 amRNSForm 8.3 - Pfizer Inc
27th May 201411:15 amRNSForm 8.3 - Pfizer Inc
27th May 201411:12 amRNSForm 8.3 - Pfizer Inc
27th May 20149:52 amRNSRule 2.10 Announcement
27th May 20147:00 amRNSANNOUNCEMENT REGARDING ASTRAZENECA PLC
27th May 20147:00 amRNSForm 8 (DD) - [Pfizer Inc]
27th May 20147:00 amRNSForm 8 (DD) - [Pfizer Inc]
27th May 20147:00 amRNSForm 8.5 (EPT/RI)
27th May 20147:00 amRNSForm 8.3 - Pfizer Inc
27th May 20147:00 amRNSForm 8.3 - AstraZeneca Plc
27th May 20147:00 amRNSForm 8.3 - [PFIZER INC]
23rd May 20145:50 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
23rd May 20145:48 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
23rd May 20144:40 pmRNSForm 8.3 - AstraZeneca PLC
23rd May 20144:37 pmRNSForm 8.3 - Pfizer Inc
23rd May 20143:49 pmRNSForm 8.5 (EPT/RI)-Pfizer Inc. Amendment
23rd May 20143:15 pmRNSForm 8.3 - Pfizer Inc
23rd May 20143:13 pmRNSForm 8.3 - [Pfizer Inc]
23rd May 20143:12 pmBUSForm 8.3 - Pfizer Inc.
23rd May 20143:11 pmBUSForm 8.3 - Pfizer Inc
23rd May 20142:58 pmRNSForm 8.3 - [PFIZER INC]
23rd May 20142:54 pmRNSForm 8.3 - Pfizer Inc
23rd May 20142:51 pmRNSForm 8.3 - Pfizer Inc
23rd May 20142:49 pmRNSForm 8.3 - Astrazeneca PLC
23rd May 20142:48 pmRNSForm 8.3 - Pfizer Inc
23rd May 20142:24 pmRNSForm 8.3 - Pfizer Inc
23rd May 20142:23 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
23rd May 20142:22 pmRNSForm 8.3 - AstraZeneca Plc
23rd May 20141:45 pmBUSForm 8.3 - Pfizer Inc
23rd May 20141:44 pmBUSForm 8.3 - Pfizer Inc
23rd May 201412:56 pmRNSForm 8 (DD) - Pfizer Inc.
23rd May 201412:36 pmRNSForm 8.3 - Pfizer Inc
23rd May 201412:27 pmRNSForm 8.3 - AstraZeneca Plc
23rd May 201412:25 pmRNSForm 8.3 - Pfizer Inc
23rd May 201412:14 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.